EYES - Second Sight Medical Products, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.7730
+0.0030 (+0.39%)
At close: 4:00PM EDT

0.7344 -0.04 (-4.99%)
After hours: 5:40PM EDT

Stock chart is not supported by your current browser
Previous Close0.7700
Open0.7750
Bid0.7500 x 900
Ask0.8500 x 1200
Day's Range0.7600 - 0.7750
52 Week Range0.6350 - 1.9800
Volume51,889
Avg. Volume208,165
Market Cap96.305M
Beta (3Y Monthly)1.38
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Business Wire

     Second Sight Reports Second Quarter 2019 Financial Results

    -- R&D and Clinical Programs for Orion® Visual Cortical Prosthesis System on Track --

  • Business Wire

    Second Sight to Discuss Second Quarter 2019 Financial Results on August 6, 2019 Conference Call

    Second Sight Medical Products, Inc. (EYES), a developer, manufacturer and marketer of implantable visual prosthetics intended to create an artificial form of useful vision for blind individuals, will release its financial results for the second quarter of 2019 on Tuesday, August 6, 2019, after the close of the U.S. financial markets. A recognized global leader in neuromodulation devices for blindness, the Company is committed to developing new technologies to treat the broadest population of sight-impaired individuals.

  • Business Wire

    Researchers Present Latest Positive Results of Second Sight’s Orion Visual Cortical Prosthesis Feasibility Study

    Second Sight Medical Products, Inc. (EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics intended to create an artificial form of useful vision for blind individuals, announced that 12-month results from the Company’s Early Feasibility Study of the Orion® Visual Cortical Prosthesis System (“Orion”) will be presented today at the World Society for Stereotactic and Functional Neurosurgery Annual Meeting in New York City. On both the primary and secondary outcome measures, latest results at 12 months have been positive.

  • Business Wire

    Second Sight to Present at 20th Annual B. Riley FBR Investor Conference

    The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.secondsight.com, under the Investors Section. Second Sight Medical Products, Inc. (EYES) develops, manufactures and markets implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals.

  • Business Wire

    Second Sight Reports First Quarter 2019 Financial Results

    -- Company to Accelerate Development of Orion® Visual Cortical Prosthesis System --

  • Business Wire

    Second Sight to Accelerate Development of Orion® Visual Cortical Prosthesis System

    Second Sight Medical Products, Inc. (EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced its plan to accelerate the development and commercialization of its Orion Visual Cortical Prosthesis System (“Orion”). Orion holds the potential to provide useful artificial vision to individuals blind from many causes, including glaucoma, eye injury, diabetic retinopathy, optic nerve disease or injury, and retinitis pigmentosa (“RP”).

  • Business Wire

    Second Sight to Discuss First Quarter 2019 Financial Results on May 15, 2019 Conference Call

    Second Sight Medical Products, Inc. (EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, will release its financial results for the first quarter of 2019 on Wednesday, May 15, 2019, after the close of the U.S. financial markets. All statements in this release that are not based on historical fact are “forward looking statements.” These statements may be identified by words such as “estimates,” “anticipates,” “projects,” “plans,” “goal,” or “planned,” “seeks,” “may,” “will,” “expects,” “intends,” “believes,” “should,” and similar expressions, or the negative versions thereof, and which also may be identified by their context.

  • Business Wire

    Second Sight Medical Products, Inc. Presents Positive Interim Results at the Fifth Annual BRAIN Initiative® Investigators Meeting

    Second Sight Medical Products, Inc. (EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that the Company will present an update on its Early Feasibility Study of the Orion® Visual Cortical Prosthesis System (“Orion”) at the Fifth Annual BRAIN Initiative® Investigators Meeting being held at the Marriott Wardman Park Hotel in Washington, D.C. on April 11, 2019.

  • Business Wire

    Second Sight Reports Fourth Quarter and Full Year 2018 Financial Results

    Second Sight Medical Products, Inc. , a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today reported financial results for the three months and year ended December 31, 2018.

  • Business Wire

    Second Sight to Discuss Fourth Quarter and Year-End 2018 Financial Results on March 13, 2019 Conference Call

    Second Sight Medical Products, Inc. (EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, will release its 2018 fourth quarter and year-end financial results on Wednesday, March 13, 2019, after the close of the U.S. financial markets. The Company’s U.S. headquarters are in Los Angeles, California and European headquarters are in Lausanne, Switzerland.

  • Business Wire

    Second Sight Medical Products, Inc. Announces Completion of Rights Offering

    Second Sight Medical Products, Inc. (EYES) ("Second Sight" or the “Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the completion of its rights offering, which expired at 5:00 p.m. New York time on February 15, 2019. The Company has received aggregate gross proceeds from the rights offering of approximately $34.6 million. The results of the rights offering, including the allocation of units, shares and warrants to be issued in the rights offering, are preliminary and subject to change pending the expiration of the guaranteed delivery period under the offering and finalization of subscription procedures by Broadridge Corporate Issuer Solutions, Inc. which acted as the subscription agent and information agent for the offering.

  • GlobeNewswire

    Recent Analysis Shows Abercrombie & Fitch, DaVita, W.W. Grainger, Ingredion, FirstEnergy, and Second Sight Medical Products Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, Jan. 22, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire

    Second Sight Medical Products, Inc. Announces $40 Million Rights Offering of Units and Two Year Extension of Warrants (EYESW) Expiration Date

    Second Sight Medical Products, Inc. (EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced a rights offering to raise $40 million. Holders of our common stock on January 15, 2019, the record date, will be able to participate in the rights offering.

  • GlobeNewswire

    Second Sight Reports Fourth Quarter 2018 Business Update

    -- Full Year 2018 net revenue estimated to be in the range of $6.5-$6.9 million -- -- 6th Orion patient scheduled for implantation at Baylor Medical Center -- LOS ANGELES,.

  • GlobeNewswire

    Second Sight to Present at Digital Medicine and Medtech Showcase 2019

    LOS ANGELES, Dec. 20, 2018 -- Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual.

  • GlobeNewswire

    Second Sight Completes $3 million Private Placement of Common Stock with Gregg Williams, Chairman of the Board of Directors

    Second Sight Medical Products, Inc. (EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that it has entered into a stock purchase agreement effective December 12, 2018 with entities beneficially owned by Gregg Williams, Chairman of the Board of Directors of Second Sight, for the purchase of  3,275,100 shares of common stock priced at $0.916 per share, the last reported sale price of the common stock on the effective date. This placement of common stock is anticipated to yield gross proceeds of approximately $3 million to the Company.

  • GlobeNewswire

    Second Sight to Present at the 11th Annual LD Micro Main Event Conference in Los Angeles on Wednesday, December 5th

    The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.secondsight.com, under the Investor Relations section. Conference participation is by invitation only and registration is mandatory.

  • GlobeNewswire

    Research Report Identifies Prudential Financial, Second Sight Medical Products, Acushnet, Repligen, Scorpio Tankers, and Aethlon Medical with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Nov. 12, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire

    Second Sight Reports Third Quarter 2018 Financial Results

    Encouraging Interim Results of Orion® Feasibility Study with Four Subjects Cleared for Home Use LOS ANGELES, Nov. 07, 2018 -- Second Sight Medical Products, Inc. (NASDAQ:.

  • GlobeNewswire

    Second Sight Announces Final 2019 Medicare Hospital Outpatient Payment Rate for the Argus II Retinal Prosthesis System

    Second Sight Medical Products, Inc. (EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that the Centers for Medicare & Medicaid Services (CMS) has finalized its Medicare hospital outpatient payment rate of $152,500 for the Argus® II Retinal Prosthesis System (Argus II) and the associated surgical implantation procedure for calendar year 2019.

  • Business Wire

    Second Sight to Discuss Third Quarter 2018 Financial Results on November 7, 2018 Conference Call

    Second Sight Medical Products, Inc. (EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind individuals, will release its 2018 third quarter financial results on Wednesday, November 7, 2018, after the close of the U.S. financial markets. In 2016, the Company published five year results.

  • Business Wire

    Second Sight Completes $4 million Private Placement of Common Stock with Gregg Williams, Chairman of the Board of Directors

    Second Sight Medical Products, Inc. (EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind individuals, today announced that it has entered into a stock purchase agreement effective October 18, 2018 with entities beneficially owned by Gregg Williams, Chairman of the Board of Directors of Second Sight, for the purchase of 2,467,727 shares of common stock priced at $1.62 per share, the last reported sale price of the common stock on the effective date. This placement of common stock is anticipated to yield gross proceeds of approximately $4 million to the Company.

  • Business Wire

    Second Sight Receives $1.6 Million Grant from National Institutes of Health to Support Orion Clinical Development

    Second Sight Medical Products, Inc. (EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind individuals, today announced that the Company has received a $1.6 million grant (with the intent to fund $6.3 million over five years subject to annual review and approval) from the National Institutes of Health (NIH) to fund the “Early Feasibility Clinical Trial of a Visual Cortical Prosthesis” that commenced in January 2018.

  • Business Wire

    Second Sight Appoints Pat Ryan Chief Operating Officer

    Second Sight Medical Products, Inc. (EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, announced today that Pat Ryan has been appointed Chief Operating Officer, effective immediately. In this newly created role, Mr. Ryan will assume responsibility for Research & Development, Manufacturing, Planning & Materials, Quality Assurance, and Information Technology. “Pat brings a wealth of knowledge from both large and small medical device firms, and we are delighted to welcome him to the Second Sight team.